Biosimilar
FDA Approves First Interchangeable Omalizumab Biosimilar
The FDA announced it has approved a biosimilar version of omalizumab. The drug, which will be marketed as Omlyclo ...
MARCH 7, 2025
Regulatory Reform Needed to Drive Biosimilar Adoption
Biosimilars generated $12.4 billion in savings in 2023, bringing the total savings since their introduction in 2015 ...
DECEMBER 14, 2024
FDA Approves Pyzchiva Biosimilar to Stelara
Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...
JULY 16, 2024
FDA Approves Wezlana, an Interchangeable Biosimilar for Stelara
An interchangeable designation means the biosimilar may be substituted for the reference product without consulting ...
NOVEMBER 1, 2023
Pharmacists Can Help Drive Biosimilars Growth
As medication experts and some of the most accessible members of the healthcare team, pharmacists are well ...
JUNE 2, 2022
Third Biosimilar to Bevacizumab Approved
The FDA approved bevacizumab-maly (Alymsys, Amneal Pharmaceuticals), a biosimilar to bevacizumab (Avastin, ...
APRIL 19, 2022
The Case for Switching to Rituximab Biosimilar
Switching from originator rituximab (Rituxan, Genentech) to rituximab-abbs (Truxima, Teva) can save an institution ...
FEBRUARY 9, 2022
Semglee First Biosimilar to Receive FDA Interchangeable Product Designation
As an interchangeable biosimilar product, insulin glargine-yfgn may be substituted for the reference product at the ...
JULY 29, 2021
Strategies for Boosting Biosimilar Uptake
Use of biosimilars could increase if stakeholders, from manufacturers to payors and pharmacists, united to employ ...
MAY 27, 2021
Supreme Court Denies Sandoz Petition to Review Biosimilar Patent Suit
The two companies have been in a "patent dance" for several years.
MAY 17, 2021
FDA Approves Riabni, Third Biosimilar to Rituxan
The FDA Approved Amgen's Riabni, the 3rd biosimilar to the originator, U.S.-licensed Rituxan.
DECEMBER 18, 2020
SubQ Infliximab Holds Up Against IV Form for IBD
Patients with inflammatory bowel disease are one step closer to having a subcutaneous version of infliximab.
SEPTEMBER 11, 2020
